<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138277</url>
  </required_header>
  <id_info>
    <org_study_id>ATB200-07</org_study_id>
    <nct_id>NCT04138277</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD</brief_title>
  <official_title>A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, international open-label extension study of ATB200/AT2221 in adult
      subjects with late-onset Pompe disease (LOPD) who completed Study ATB200-03.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label extension study for subjects who completed the ATB200-03 study. The
      subjects will stay in this study until regulatory approval or marketing authorization and/or
      commercialization in the participating subject's country.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
    <description>Change in 6MWD from baseline to assess the efficacy of ATB200/AT2221 co-administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function - Forced vital capacity (FVC)</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
    <description>Change from baseline in FVC (sitting) to assess the efficacy of ATB200/AT2221 co-administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in muscle strength measured by Quantitative Muscle Strength testing</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in muscle strength measured by Manual Muscle Strength testing</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rasch-built Pompe-specific activity (R-PAct) questionnaires</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
    <description>Change in R-Pact from baseline to assess the efficacy of ATB200/AT2221 co-administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaires</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
    <description>Change from baseline in scores of EQ-5D-5L questionnaire to assess the efficacy of ATB200/AT2221 co-administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in scores of PROMIS - physical function questionnaire</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in scores of PROMIS - fatigue questionnaire</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in scores of PROMIS - dyspnea questionnaire</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in scores of PROMIS - upper extremity questionnaire</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Function - Gait, Stairs, Gower, Chair (GSGC) test</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
    <description>Change from baseline in GSGC score to assess the efficacy of ATB200/AT2221 co-administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Impression of Change</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
    <description>Change in the Physician's Global Impression of Change (PGIC) evaluation to assess the efficacy of ATB200/AT2221 co-administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Global Impression of Change</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
    <description>Change from baseline in scores of Subject's Global Impression of Change (SGIC) questionnaire to assess the efficacy of ATB200/AT2221 co-administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Biomarker -CK</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Biomarker -uHex4</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Incidence of neutralizing</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: anti-drug antibodies</measure>
    <time_frame>baseline, up to approximately 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Pompe Disease (Late-onset)</condition>
  <arm_group>
    <arm_group_label>ATB200/AT2221</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ATB200 co-administered with AT2221 capsule (Miglustat)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT2221</intervention_name>
    <description>Participants received ATB200 co-administered with AT2221 (Miglustat)</description>
    <arm_group_label>ATB200/AT2221</arm_group_label>
    <other_name>Miglustat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATB200</intervention_name>
    <description>Enzyme Replacement Therapy via intravenous infusion</description>
    <arm_group_label>ATB200/AT2221</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Subject must have completed Study ATB200-03.

        Exclusion Criteria

          1. Subject plans to receive gene therapy or participate in another interventional study
             for Pompe disease.

          2. Subject, if female, is pregnant or breastfeeding.

          3. Subject, whether male or female, is planning to conceive a child during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>For Site</last_name>
    <phone>609-662-2000</phone>
    <email>PompeSiteInfo@amicusrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For Patient</last_name>
    <phone>609-662-2000</phone>
    <email>patientadvocacy@amicusrx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Gardner Neuroscience Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Montefiore Clinical and Translational Research Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lysosomal and Rare Disorders Research and Treatment Center, Inc.</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska</name>
      <address>
        <city>Banja Luka</city>
        <state>The Republic Of Srpska</state>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique Pierre</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pécs</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Medyk</name>
      <address>
        <city>Rzeszów</city>
        <state>Podkarpackie</state>
        <zip>35-326</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pompe</keyword>
  <keyword>rhGAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

